Oxford BioMedica has reaffirmed its trimmed 2026 revenue range after a first half of record client wins, leaving investors focused on whether its new North Carolina site can deliver the promised second-half acceleration.
The gene and cell therapy contract manufacturer has spent the past two months trying to rebuild confidence after a difficult summer. On 7 August, Oxford BioMedica (LSE: OXB) told the market that full-year 2026 revenue would come in at £180m to £200m on a constant-currency basis, citing client deferrals, programme timelines shifting on the back of clinical data, a change in procurement approach at one larger customer, and a six-month delay in bringing its Durham, North Carolina facility to operational readiness. That range sat well below the £220m to £240m the group had pointed to alongside its 2025 results earlier in the year.
Interims confirm the reset
The interim results published on 22 September broadly matched the August pre-announcement. Revenue for the six months to 30 June rose 9% to £79.8m, or 10% to £80.2m at constant currency. The group recorded an operating EBITDA loss of £7.8m, slightly narrower than the £8.3m loss a year earlier; stripping out one-off items and currency effects, the underlying loss was £2.5m against £3.9m in the first half of 2025.
Commercial momentum was the brighter part of the update. The company signed a record 17 new clients during the half and a further four after the period end, taking its roster to 50 clients across 59 programmes. The revenue backlog stood at around £193m, and management said roughly £168m of forecast 2026 revenue was already covered by contracted orders. Chief executive Dr Frank Mathias described the first half as commercially strong and said the Durham site was now operationally ready and serving clients, with its first GMP manufacturing run completed.
Guidance was reiterated in full. For 2026 the group expects a mid-single-digit EBITDA margin excluding one-off costs, or a low-single-digit margin on a reported basis. For 2027 it continues to target revenue growth of 25% to 30% and at least a double-digit EBITDA margin, while retaining a longer-term ambition of around £500m of revenue by 2030 with margins approaching 30% as volumes scale.
Cash and the balance sheet
The balance sheet is where investors have been looking most closely. Cash fell to £75.3m at 30 June from £96.9m at the end of 2025, and net cash dropped to £21.4m from £55.4m. Oxford BioMedica drew a further $15m from its Oaktree Capital loan facility in March, which has a total principal of $125m, and borrowings on the balance sheet totalled £53.8m at the half-year. The outflow reflects both the first-half losses and the investment needed to integrate and ramp the US site, so the pace at which Durham converts into billable activity will matter for cash as much as for revenue.
The shares slipped on results day as the market weighed the client wins against lower margins and heavier cash use. Since then, director dealings have been modest: on 28 September non-executive vice chair Peter Soelkner bought a small number of shares, while a US-based executive sold shares on 6 October after the vesting of long-term incentive awards.
What comes next
The investment case now rests heavily on second-half delivery. The group has guided to a materially stronger second half, which implies a sharp step-up in revenue from the £80m booked in the first six months. Evidence that Durham is filling with client work, that deferred programmes are moving forward and that the 2027 growth target remains intact is likely to be the main yardstick when the company next updates the market.






Please wait processing your request...